40 Cities with the Highest Life Expectancy in the US

In This Article:

In this article, we look at 40 Cities With The Highest Life Expectancy In The US. You can skip our detailed analysis on companies that are working on longevity enhancement and improved health facilities by heading over directly to the 10 Cities With The Highest Life Expectancy In The US.

Life expectancy of a newborn has more than doubled globally, from an average life of 32 years in 1900, to 71 years in 2021. This stark shift has been driven by remarkable advancements in medicine, public health facilities, and an improvement in living standards. These factors have combined to significantly reduce child mortality and increased life expectancy at all ages.

Average lifespan has also been on the rise in the United States. It was 47 years in 1900 and climbed to 68 by 1950. It nearly touched 79 years in 2019 before the coronavirus pandemic struck. Over the last few years, it has started to decline, driven by Covid-19 and cases of drug overdose, according to a report by Harvard University. Life Expectancy fell to 77 years in 2020, before further dropping to 76 in 2021.

Scientific research and studies are underway in the US to enhance longevity. Eli Lilly and Company (NYSE:LLY) is actively working to combat chronic diseases. This month, the FDA approved Jaypirca, an anti-cancer drug that will be used to treat patients of lymphocytic leukemia. Eli Lilly and Company (NYSE:LLY) announced that this medication can be used for treatment of patients who have received at least two lines of therapy. Eli Lilly and Company (NYSE:LLY)’s Jaypirca is the first-ever non-covalent BTK inhibitor to be approved.

American biotechnology company Altos Labs, Inc., founded in 2022, is working to develop specialized cell therapies that extend lifespan and limit the human aging process. The company has so far received $3 billion in investor funding. On the other hand, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is using artificial intelligence in biology, chemistry and machine learning to reinvent drug discovery and speed up pharmaceutical development.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s main aim is to develop an AI platform that lowers the costs and time spent on drug development, and reduce the rate of late-stage clinical failures. In November this year, German pharmaceutical company, Bayer AG, pledged up to $1.5 billion to work with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) on seven oncology and cancer treatment related projects.

Denali Therapeutics Inc. (NASDAQ:DNLI) is pursuing treatments that improve the lives of patients suffering from neurodegenerative diseases. Denali Therapeutics Inc. (NASDAQ:DNLI)’s innovations are likely to have wide-ranging effects, especially on patients of Parkinson’s and other neurodegenerative illnesses. Founded in 2013, Denali Therapeutics Inc. (NASDAQ:DNLI) is still a young company whose revenue model is reliant significantly on collaboration agreements with other corporations. In 2020, Biogen announced to co-develop with Denali the leucine-rich repeat kinase 2 (LRRK2) program for Parkinson’s disease. Under the agreement, Denali Therapeutics Inc. (NASDAQ:DNLI) received a payment of $560 million, and $465 million in equity investment.